CoChat

T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Abstract Targeted delivery of compounds to particular cell subsets can enhance therapeutic index by concentrating their action on the cells of interest. Because attempts to target tumors directly have yielded limited benefit, we instead target endogenous immune cell subsets in the circulation that can migrate actively into tumors. We describe antibody-targeted nanoparticles that bind to CD8 + T cells in the blood, lymphoid tissues, and tumors of mice. PD-1 + T cells are successfully targeted in the circulation and tumor. The delivery of an inhibitor of TGFβ signaling to PD-1-expressing cells extends the survival of tumor-bearing mice, whereas free drugs have no effect at such doses. This modular platform also enables PD-1-targeted delivery of a TLR7/8 agonist to the tumor microenvironment, increasing the proportion of tumor-infiltrating CD8 + T cells and sensitizing tumors to subsequent anti-PD-1. Targeted delivery of immunotherapy to defined subsets of endogenous leukocytes may be superior to administration of free drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-01830-8

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Optimization of F(ab’)2 conjugation to polymeric nanoparticles. a Scheme of antibody fragment conjugation to the surface of pre-formulated maleimide-functionalized PEG-PLGA polymeric nanoparticles (NPs). b A non-reducing SDS–PAGE gel stained with Coomassie Brilliant Blue is shown following IdeS-mediated cleavage of anti-CD8a and rat IgG2b isotype control antibodies. c A Western blot following reducing SDS–PAGE of CD8a-targeting nanoparticles developed with Fab-specific (left panel) or Fc-specific antibodies (right panel); lane 1: uncoated nanoparticles, lane 2: nanoparticles without antibody reduction before conjugation, lane 3: anti-CD8a nanoparticles with the antibody reduced using 0.5 mM DTT before conjugation, lane 4: anti-CD8a F(ab’)2 and Fc cleavage product as a positive control. d Scanning electron microscopy images of blank NP formulations before and after F(ab’)2 conjugation; scale bar = 500 nm
Fig. 1 Optimization of F(ab’)2 conjugation to polymeric nanoparticles. a Scheme of antibody fragment conjugation to the surface of pre-formulated maleimide-functionalized PEG-PLGA polymeric nanoparticles (NPs). b A non-reducing SDS–PAGE gel stained with Coomassie Brilliant Blue is shown following IdeS-mediated cleavage of anti-CD8a and rat IgG2b isotype control antibodies. c A Western blot following reducing SDS–PAGE of CD8a-targeting nanoparticles developed with Fab-specific (left panel) or Fc-specific antibodies (right panel); lane 1: uncoated nanoparticles, lane 2: nanoparticles without antibody reduction before conjugation, lane 3: anti-CD8a nanoparticles with the antibody reduced using 0.5 mM DTT before conjugation, lane 4: anti-CD8a F(ab’)2 and Fc cleavage product as a positive control. d Scanning electron microscopy images of blank NP formulations before and after F(ab’)2 conjugation; scale bar = 500 nmCC BY · PubMed Central
Fig. 2 CD8a-targeting nanoparticles bind to T cell in vitro and in vivo. a CD8a-targeting nanoparticles (loaded with DiD), but not isotype control nanoparticles, bind to the surface of CD8+ T cells isolated from the spleen within 30 min of incubation, as assessed by flow cytometry. b Quantification of DiD-positive T cells; data representative for more than 4 experiments. c Timeline of in vivo binding experiment. d Quantification of DiD-positive, CD3+/CD8+ and CD3+/CD8− T cells 1, 24, and 48 h after the nanoparticles were injected intravenously; n = 3 for 1 and 48 h, n = 6 for 24 h, mean ± s.e.m.; (red open circle) Anti-CD8a antibody for flow cytometry staining could not bind due to steric hindrance with CD8a-targeting nanoparticles. e Quantification of CD3/CD8+ T cells in blood, spleen, tumor-draining lymph node (TdLN), and tumor 24 h after the nanoparticles were injected intravenously; n = 6
Fig. 2 CD8a-targeting nanoparticles bind to T cell in vitro and in vivo. a CD8a-targeting nanoparticles (loaded with DiD), but not isotype control nanoparticles, bind to the surface of CD8+ T cells isolated from the spleen within 30 min of incubation, as assessed by flow cytometry. b Quantification of DiD-positive T cells; data representative for more than 4 experiments. c Timeline of in vivo binding experiment. d Quantification of DiD-positive, CD3+/CD8+ and CD3+/CD8− T cells 1, 24, and 48 h after the nanoparticles were injected intravenously; n = 3 for 1 and 48 h, n = 6 for 24 h, mean ± s.e.m.; (red open circle) Anti-CD8a antibody for flow cytometry staining could not bind due to steric hindrance with CD8a-targeting nanoparticles. e Quantification of CD3/CD8+ T cells in blood, spleen, tumor-draining lymph node (TdLN), and tumor 24 h after the nanoparticles were injected intravenously; n = 6CC BY · PubMed Central
Fig. 3 PD-1-targeting nanoparticles bind to T cells in vitro and in vivo. a CD8+ OT-I T cells were activated with ovalbumin-expressing B16 (ratio 1:10 B16 to T cell) for 48 h and incubated with DiD-loaded, PD-1-targeting nanoparticles for 30 min before detection of DiD by flow cytometry. Mass of polymer indicated is per 250,000 T cells. b C57BL/6 mice were inoculated subcutaneously with ovalbumin-expressing B16 melanoma cells. Once tumors reached ~400 mm3 in volume, DiD-loaded, PD-1-targeting or isotype control nanoparticles were injected intravenously. 1 h later, tumors were recovered. Flow cytometry was performed (gating shown at left), and the percentage of T cells that were positive for both PD-1 expression and nanoparticle binding was quantified (right panel); n = 5 (*p < 0.05, Two-tailed Student’s t-test)
Fig. 3 PD-1-targeting nanoparticles bind to T cells in vitro and in vivo. a CD8+ OT-I T cells were activated with ovalbumin-expressing B16 (ratio 1:10 B16 to T cell) for 48 h and incubated with DiD-loaded, PD-1-targeting nanoparticles for 30 min before detection of DiD by flow cytometry. Mass of polymer indicated is per 250,000 T cells. b C57BL/6 mice were inoculated subcutaneously with ovalbumin-expressing B16 melanoma cells. Once tumors reached ~400 mm3 in volume, DiD-loaded, PD-1-targeting or isotype control nanoparticles were injected intravenously. 1 h later, tumors were recovered. Flow cytometry was performed (gating shown at left), and the percentage of T cells that were positive for both PD-1 expression and nanoparticle binding was quantified (right panel); n = 5 (*p < 0.05, Two-tailed Student’s t-test)CC BY · PubMed Central
Fig. 4 PD-1-targeting nanoparticles bind to activated human T cells. a PD-1 expression on human CD3+ T cells following activation with anti-CD3/CD28 complex, n = 4 independent donors, mean ± s.e.m. b Dose-dependent binding of PD-1-targeting nanoparticles to 250,000 activated human T cells. c Quantification of T cells that were bound by DiD-loaded, PD-1-targeting nanoparticles; graph shows results of two donors and is representative for at least two independent experiments. d Dose-dependent binding of PD-1-targeting nanoparticles to activated and non-activated peripheral blood mononuclear cells (PBMCs), n = 4, mean ± s.e.m. e Pre-incubation of activated human T cells with free pembrolizumab (pre pembro) for 30 min blocks binding of PD-1-targeting nanoparticles (10 µg per 200,000 T cells; n = 3, mean ± s.d.) (*p < 0.05; **p < 0.01, Two-tailed student’s t-test)
Fig. 4 PD-1-targeting nanoparticles bind to activated human T cells. a PD-1 expression on human CD3+ T cells following activation with anti-CD3/CD28 complex, n = 4 independent donors, mean ± s.e.m. b Dose-dependent binding of PD-1-targeting nanoparticles to 250,000 activated human T cells. c Quantification of T cells that were bound by DiD-loaded, PD-1-targeting nanoparticles; graph shows results of two donors and is representative for at least two independent experiments. d Dose-dependent binding of PD-1-targeting nanoparticles to activated and non-activated peripheral blood mononuclear cells (PBMCs), n = 4, mean ± s.e.m. e Pre-incubation of activated human T cells with free pembrolizumab (pre pembro) for 30 min blocks binding of PD-1-targeting nanoparticles (10 µg per 200,000 T cells; n = 3, mean ± s.d.) (*p < 0.05; **p < 0.01, Two-tailed student’s t-test)CC BY · PubMed Central
Fig. 5 Targeted delivery of a TGFβR1 inhibitor (SD-208) to PD-1-expressing cells delays tumor growth and extends survival. a Proliferation of CD8+ T cells following activation with anti-CD3/CD28 beads (1:2 bead to T cell ratio) for 72 h in the presence or absence of TGFβ1 (2 ng mL−1) and treatment with 1 μM SD-208 as free compound or as nanoparticle formulation; quantification of geometric mean of cell trace violet is provided in the right panel, n = 3, mean ± s.d. b Intracellular granzyme B expression was assessed by flow cytometry, n = 3, mean ± s.d. (*p < 0.05, one-way ANOVA with Tukey’s post hoc test). c Fold change of interferon-γ (IFNγ) was measured by ELISA, n = 4, mean ± s.e.m. d, e C57BL/6 were inoculated subcutaneously with MC38 cells. Five days later, nanoparticles or free drugs were administered intravenously every other day up to a total of 10 injections. The dose was 20 μg of anti-PD-1 and 40 μg of SD-208. d Tumor volume and e animal survival were monitored to assess efficacy, n = 6, mean ± s.e.m.; (***p < 0.001, Mantel-Cox test)
Fig. 5 Targeted delivery of a TGFβR1 inhibitor (SD-208) to PD-1-expressing cells delays tumor growth and extends survival. a Proliferation of CD8+ T cells following activation with anti-CD3/CD28 beads (1:2 bead to T cell ratio) for 72 h in the presence or absence of TGFβ1 (2 ng mL−1) and treatment with 1 μM SD-208 as free compound or as nanoparticle formulation; quantification of geometric mean of cell trace violet is provided in the right panel, n = 3, mean ± s.d. b Intracellular granzyme B expression was assessed by flow cytometry, n = 3, mean ± s.d. (*p < 0.05, one-way ANOVA with Tukey’s post hoc test). c Fold change of interferon-γ (IFNγ) was measured by ELISA, n = 4, mean ± s.e.m. d, e C57BL/6 were inoculated subcutaneously with MC38 cells. Five days later, nanoparticles or free drugs were administered intravenously every other day up to a total of 10 injections. The dose was 20 μg of anti-PD-1 and 40 μg of SD-208. d Tumor volume and e animal survival were monitored to assess efficacy, n = 6, mean ± s.e.m.; (***p < 0.001, Mantel-Cox test)CC BY · PubMed Central
Fig. 6 Targeted delivery of a TLR7/8 agonist (R848) to PD-1-expressing cells promotes infiltration of CD8+ T cells into MC38 and B16 tumors. C57BL/6 mice were inoculated subcutaneously with MC38 cells (a, b) or B16 cells (c, d). Fourteen days later, a single intravenous injection was performed with the following treatment groups: (1) PBS, (2) anti-PD-1 IgG and free R848, (3) anti-PD-1 IgG and untargeted particles loaded with R848, 4) PD-1-targeting particles loaded with R848. After 72 h, tumors were collected and processed into FFPE blocks for immunohistochemistry. a, c Immunohistochemistry using anti-CD8 reveals that tumors are not highly inflamed at baseline. An increase in TILs (quantified in b, d using ImageJ software, 10 random fields per mouse, 5 mice per treatment group) is observed only if the TLR7/8 agonist is delivered via the PD-1-targeting nanoparticles. The dose per injection was 20 μg of anti-PD-1 and 60 μg of R848, n = 50, mean ± s.d. (**p < 0.01; ***p < 0.001, one-way ANOVA with Tukey’s post hoc test)
Fig. 6 Targeted delivery of a TLR7/8 agonist (R848) to PD-1-expressing cells promotes infiltration of CD8+ T cells into MC38 and B16 tumors. C57BL/6 mice were inoculated subcutaneously with MC38 cells (a, b) or B16 cells (c, d). Fourteen days later, a single intravenous injection was performed with the following treatment groups: (1) PBS, (2) anti-PD-1 IgG and free R848, (3) anti-PD-1 IgG and untargeted particles loaded with R848, 4) PD-1-targeting particles loaded with R848. After 72 h, tumors were collected and processed into FFPE blocks for immunohistochemistry. a, c Immunohistochemistry using anti-CD8 reveals that tumors are not highly inflamed at baseline. An increase in TILs (quantified in b, d using ImageJ software, 10 random fields per mouse, 5 mice per treatment group) is observed only if the TLR7/8 agonist is delivered via the PD-1-targeting nanoparticles. The dose per injection was 20 μg of anti-PD-1 and 60 μg of R848, n = 50, mean ± s.d. (**p < 0.01; ***p < 0.001, one-way ANOVA with Tukey’s post hoc test)CC BY · PubMed Central
Fig. 7 Targeted delivery of a TLR7/8 agonist (R848) to PD-1-expressing cells extends survival and sensitizes tumors to anti-PD-1. C57BL/6 mice were inoculated subcutaneously with 200,000 MC38 cells. a, b Starting on day 5, nanoparticles or free drugs were administered intravenously every other day up to a total of 10 injections. The dose was 20 μg of anti-PD-1 and 60 μg of R848 per injection. Tumor volume and animal survival were monitored to assess anti-tumor efficacy. c, d Nanoparticles or free drugs (20 μg of anti-PD-1 and 60 μg of R848) were administered intravenously on days 5, 7, and 9 post-tumor inoculation to activate the innate immune system and thereby inflame the tumor. On days 11, 14, and 17, anti-PD-1 antibody (clone 29 F.1A12, 200 μg) was injected intraperitoneally, as this IgG is typically administered. Tumor volume and animal survival were monitored to assess for efficacy (n = 6–7, mean ± s.e.m; *p < 0.05; ***p < 0.001, Mantel-Cox test)
Fig. 7 Targeted delivery of a TLR7/8 agonist (R848) to PD-1-expressing cells extends survival and sensitizes tumors to anti-PD-1. C57BL/6 mice were inoculated subcutaneously with 200,000 MC38 cells. a, b Starting on day 5, nanoparticles or free drugs were administered intravenously every other day up to a total of 10 injections. The dose was 20 μg of anti-PD-1 and 60 μg of R848 per injection. Tumor volume and animal survival were monitored to assess anti-tumor efficacy. c, d Nanoparticles or free drugs (20 μg of anti-PD-1 and 60 μg of R848) were administered intravenously on days 5, 7, and 9 post-tumor inoculation to activate the innate immune system and thereby inflame the tumor. On days 11, 14, and 17, anti-PD-1 antibody (clone 29 F.1A12, 200 μg) was injected intraperitoneally, as this IgG is typically administered. Tumor volume and animal survival were monitored to assess for efficacy (n = 6–7, mean ± s.e.m; *p < 0.05; ***p < 0.001, Mantel-Cox test)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 468

Metadata

Authors
Schmid, D., Park, C. G., Hartl, C. A., Subedi, N., Cartwright, A. N., Puerto, R. B., Zheng, Y., Maiarana, J., Freeman, G. J., Wucherpfennig, K. W., Irvine, D. J., & Goldberg, M. S.
Affiliations
  • Harvard University (US)
  • Dana-Farber Cancer Institute (US)
  • Koch Institute for Integrative Cancer Research At MIT (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Goldberg, Michael S.
Venue
Nature Communications
Published
2017-11-23
Volume
8
Issue
1
Pages
1747-1747
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2768778626
Cited by
449
References
48
Citations by year
2026: 28 · 2025: 39 · 2024: 43 · 2023: 50 · 2022: 66 · 2021: 78 · 2020: 72 · 2019: 54 · 2018: 17
FWCI
14.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
  • Nature
Funders
  • Melanoma Research Alliance
  • Dana-Farber/Harvard Cancer Center
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
antibody-targeted nanoparticles, CD8+ T cells, PD-1, TGF-beta inhibition, TLR7/8 agonist, tumor-infiltrating CD8+ T cells, antitumor immunity, targeted drug delivery, combination immunotherapy, tumor microenvironment
MeSH terms
Animals, Female, Humans, Imidazoles, Immunotherapy, Male, Melanoma, Experimental, Membrane Glycoproteins, Mice, Inbred C57BL, Neoplasms, Experimental, Transforming Growth Factor beta, Lymphocytes, Tumor-Infiltrating, Drug Delivery Systems, Mice, Knockout, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Toll-Like Receptor 7, Toll-Like Receptor 8, Mice, Nanoparticles, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. https://app.cochat.ai/papers/10.1038/s41467-017-01830-8
The paper
Schmid, D., Park, C. G., Hartl, C. A., Subedi, N., Cartwright, A. N., Puerto, R. B., Zheng, Y., Maiarana, J., Freeman, G. J., Wucherpfennig, K. W., Irvine, D. J., & Goldberg, M. S. (2017). T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nature Communications. https://doi.org/10.1038/s41467-017-01830-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.